bioMerieux
VC Fund
Marcy-l'etoile, France
bioMerieux is a VC fund in Marcy-l'etoile focused on Biotechnology and Health Care. BioMerieux designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications.The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms,and autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret biological test results; and other related services such as the installation and maintenance of instruments, user training, and the audit of laboratory workflows.BioMerieux offers diagnostic systems for clinical applications including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples such as blood, saliva, and urine; and for industrial applications including the analysis of microbiological manufacturing such as food, pharmaceuticals, and cosmetics.The company markets and sells its products through a network of distributors to private sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America.BioMerieux were founded in 1963 and is headquartered in Marcy l’Etoile, France. It is a subsidiary of Institut Mérieux.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries bioMerieux invests in
Stages bioMerieux invests in
Countries bioMerieux invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony Manganaro
|
|||
Bob Korman
|
|||
Carine Malcus-Vocanson
|
|||
Ed Klosterman
|
|||
Eric Thomas
|
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 5 (42%)
- Health Diagnostics 4 (33%)
- Medical Device 3 (25%)
- Life Science 2 (17%)
Stage
- Seed 2 (17%)
- Series B 2 (17%)
- Series C 2 (17%)
- Corporate Round 2 (17%)
- Series D 1 (8%)
Country
- United States 5 (42%)
- China 1 (8%)
- Canada 1 (8%)
- France 1 (8%)
- Israel 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anthony Manganaro
Head of Supply Chain - Americas
|
Head of Supply Chain - Americas | Total investments: 0 | Find email | |
|
Bob Korman
Manager, Center of Capabilities & Agility
|
Manager, Center of Capabilities & Agility | Total investments: 0 | Find email | |
|
Carine Malcus-Vocanson
Director, Global Clinical Affairs ImmunoAssays, Molecular Biology and Global Bioethics compliance
|
Director, Global Clinical Affairs ImmunoAssays, Molecular Biology and Global Bioethics compliance | Total investments: 0 | Find email | |
|
Ed Klosterman
Director, US Field Service Operations
|
Director, US Field Service Operations | Total investments: 0 | Find email | |
|
Eric Thomas
Director Supply & Demand
|
Director Supply & Demand | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Plair
|
Plair SA designs, manufactures, and commercializes instruments for continuous real-time measurements of fine particles in the air. It offers solutions for airborne allergen monitoring, air quality monitoring, and bioaerosol monitoring.The company’s proprietary product, Particle Analyzer PA-300, does real-time particle detection, identification,and classification. It differentiates between a wide number of disparate entities, including pollen species, organic particles such as fungal spores, inorganic particles such as soot and Saharan dust or sand, and pollutants such as polycyclic aromatic hydrocarbons. The detector identifies multiple species simultaneously and enables an understanding of atmospheric aerosol concentration.Plair SA was founded in 2014 and is based in Geneva, Switzerland. It is a spin-off from the University of Geneva. | $1.3M / Corporate Round / Mar 16, 2026 | |
Allergen Alert
|
Allergen Alert raises awareness and provides resources to help individuals manage and prevent allergic reactions safely. | $4.2M / Seed / Oct 14, 2025 | |
Oxford Nanopore Technologies
|
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use.Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. Theseinclude large scale human genomics, cancer research, microbiology, plant science, and environmental research.Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education.Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data.Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX.Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores. | $84.9M / Post-IPO Equity / Oct 19, 2023 | |
Proxim Diagnostics
|
Proxim Diagnostics develops a next generation handheld immuno diagnostic device.It performs the most important laboratory tests near the patient using whole blood without any sacrifice in sensitivity and precision. Proxim Diagnostics' device can also test blood gases, electrolytes and metabolites, infectious disease antigens and antibodies.Special attention was given to the disposable test cartridge, which can be manufactured at a low cost. Proxim’s unique combination of high performance and low cost not only make it ideal for hospital Emergency Departments in the USA but also in other settings around the world. | Corporate Round / Mar 21, 2023 | |
InDevR
|
InDevR is a biotechnology company that develops and manufactures microarray technologies and applications as well as novel solutions to support the life sciences industry. It was incorporated in 2003 and is based in Boulder, Colorado. | $9M / Series B / Jan 17, 2023 | |
accunome
|
accunome is a high-tech enterprise focusing on the in vitro diagnostic industry. | Private Equity / Dec 18, 2022 | |
|
Proxim Diagnostics
|
Proxim Diagnostics develops a next generation handheld immuno diagnostic device.It performs the most important laboratory tests near the patient using whole blood without any sacrifice in sensitivity and precision. Proxim Diagnostics' device can also test blood gases, electrolytes and metabolites, infectious disease antigens and antibodies.Special attention was given to the disposable test cartridge, which can be manufactured at a low cost. Proxim’s unique combination of high performance and low cost not only make it ideal for hospital Emergency Departments in the USA but also in other settings around the world. | $18M / Venture - Series Unknown / Nov 29, 2022 | |
Accellix
|
Accelix is a biotechnology company that helps cell and gene therapy companies to meet their key product QC requirements. It provides an instrument and a room temperature stable cartridge to gather multi-parameter results. The company was founded in 2007 and headquartered in Yerushalayim, Israel. | $9.5M / Series D / Jun 11, 2020 | |
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | $20M / Series B / Dec 04, 2017 | |
Quanterix
|
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small moleculeswithin complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come. | $18.5M / Series C / Nov 15, 2012 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does bioMerieux invest in?
bioMerieux invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Seed and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact bioMerieux?
Public channels for bioMerieux include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at bioMerieux?
The team at bioMerieux includes Anthony Manganaro (Head of Supply Chain - Americas), Bob Korman (Manager, Center of Capabilities & Agility) and Carine Malcus-Vocanson (Director, Global Clinical Affairs ImmunoAssays, Molecular Biology and Global Bioethics compliance), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
